|
7:00 am
REGISTRATION & NETWORKING BREAKFAST
7:30 am
LONGWOOD FUND INTRODUCTION
Christoph Westphal, General Partner, Longwood Fund
8:00 am
BIG BIOPHARMA PIPELINE SOURCING
Shiva Malek, Global Head, Oncology, Novartis
Frank Nestle, Global Head, Research & CSO, Sanofi
Moderator: Cody Powers, Principal, ZS Associates
8:30 am
CROSS-BORDER COLLABORATION
Ed Hu, Vice Chair & Global CIO, WuXi
Richard Paulson, CEO, Karyopharm
Nikolay Savchuk, Managing Partner, TealTech
Moderator: James Sapirstein, CEO, First Wave BioPharma
9:00 am
FIRESIDE CHAT
Lloyd Minor, Dean, Stanford School of Medicine
Marc Tessier-Lavigne, former President, Stanford University
Moderator: Christoph Westphal, General Partner, Longwood Fund
9:20 am
ENSURING HEALTH EQUITY AND ACCESS
Steve Hahn, CEO, Harbinger Health; former Commissioner, FDA
Aida Habtezion, CMO, Head, WW Medical & Safety, Pfizer
Sabrina Johnson, CEO, Daré Bioscience
Cindy Perettie, EVP, Kite, a Gilead Company
Moderator: Ariel Katz, CEO, H1
9:50 am
NETWORKING BREAK
10:20 am
R&D COLLABORATION
Nenad Grmusa, CEO, DEM BioPharma
Sek Kathiresan, CEO, Verve Therapeutics
Johan Luthman, EVP, R&D, Lundbeck
Ryan Richardson¸ Chief Strategy Officer, BioNTech
Moderator: Zhen Su, CEO, Marengo Therapeutics
10:50 am
ACCELERATING DRUG DEVELOPMENT
Judy Chou, CEO, AltruBio
Fabrice Couraqui, CEO, Cellarity
Larry Hamann, CEO, Interdict Bio
Carl Hansen, CEO, Abcellera
Moderator: Jim Anthony, President, Parexel
11:20 am
RECRUITING AND RETAINING TALENT
Luba Greenwood, CEO, Kojin Therapeutics
Quita Highsmith, Chief Diversity Officer, Genentech
Catherine Sohn, Board Director, Jazz Pharmaceuticals
11:50 am
FIRESIDE CHAT: FROM PHARMA TO BIOTECH CEO
Henry Gosebruch, CEO, Neumora
Mathai Mammen, CEO, FogPharma
12:10 pm
NETWORKING LUNCHEON
1:00 pm
RARE DISEASE INNOVATION
Ioannis Sapountzis, Corporate SVP & Global Head, Therapeutic Areas, Boehringer Ingelheim
Shalini Sharp, former CFO, Ultragenyx
Moderator: Brinda Balakrishnan, CBDO, Biomarin
1:30 pm
GETTING TO REGULATORY APPROVAL
Sandi Dunn, CEO, Phoenix Molecular Designs
Marshall Fordyce, CEO, Vera Therapeutics
Thomas Lonngren, Chair, Egetis Therapeutics; former Executive Director, EMA
Pascal Touchon, CEO, Atara
2:00 pm
DEAL-MAKING LANDSCAPE
Philippe Lopes-Fernandes, CBO, Ipsen
George Magrath, CEO, Ocuphire Pharma
George Montgomery, CFO, Neuvogen
Moderator: Mark McKenna, CEO (former), Prometheus Biosciences
2:30 pm
INNOVATIVE COMMERCIAL MODELS
Chris Benecchi, CBO, Sage Therapeutics
Teresa Bitetti, President, Global Oncology, Takeda
Arpa Garay, CCO, Moderna
Kabir Nath, CEO, COMPASS Pathways
Moderator: Steve Blaising, Co-Founder & Chair, Brain Surgery Worldwide
3:00 pm
NETWORKING BREAK
3:30 pm
REGULATORY KEYNOTE
Peter Marks, Director, CBER, FDA
4:00 pm
THE FUTURE OF GENETIC THERAPIES
Michael Amoroso, CEO, Precision BioSciences
Jason Cole, CEO, SalioGen
Gilmore O’Neill, CEO, Editas Medicine
Moderator: Alex Harding, Head, BD, CRISPR Therapeutics
4:30 pm
STRENGTH IN THE SYNDICATE
Vik Bajaj, Managing Director, Foresite Capital
Alaa Halawa, Executive Director, Mubadala
| 
